Free shipping on all orders over $ 500

JNJ-7706621

Cat. No. M1800
JNJ-7706621 Structure
Synonym:

JNJ7706621

Size Price Availability Quantity
2mg USD 70  USD70 In stock
5mg USD 120  USD120 In stock
10mg USD 210  USD210 In stock
50mg USD 560  USD560 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

JNJ-7706621 is a novel cell cycle inhibitor that showed potent inhibition of several cyclin-dependent kinases (CDK) and Aurora kinases and selectively blocked proliferation of tumor cells of various origins but was about 10-fold less effective at inhibiting normal human cell growth in vitro. In human cancer cells, treatment with JNJ-7706621 inhibited cell growth independent of p53, retinoblastoma, or P-glycoprotein status; activated apoptosis; and reduced colony formation. At low concentrations, JNJ-7706621 slowed the growth of cells and at higher concentrations induced cytotoxicity. Inhibition of CDK1 kinase activity, altered CDK1 phosphorylation status, and interference with downstream substrates such as retinoblastoma were also shown in human tumor cells following compound treatment. Flow cytometric analysis of DNA content showed that JNJ-7706621 delayed progression through G1 and arrested the cell cycle at the G2-M phase. Additional cellular effects due to inhibition of Aurora kinases included endoreduplication and inhibition of histone H3 phosphorylation. JNJ-7706621 is a unique inhibitor regulating cell cycle progression at multiple points, suggesting that it could be useful for cell cycle analysis and therapy of various cancers, including Ewing's sarcoma.

Customer Product Validations & Biological Datas
Source Oncotarget (2015). Figure 4. JNJ-7706621
Method MTT assay
Cell Lines Ovarian cancer cells
Concentrations 0.5 or 2μM
Incubation Time 4 days
Results This reveals a less than 4-fold difference in the sensitivity to JNJ-7706621 between cell lines with and without CCNE1 overexpression
Protocol (for reference only)
Cell Experiment
Cell lines HeLa cells
Preparation method Colony formation assay. HeLa cells were plated at various densities in 90-mm diameter Petri dishes and exposed to JNJ-7706621 for 48 hours. Cells were then washed in PBS and incubated an additional 7 days in drug-free medium. Cells were fixed in 95% ethanol, stained with 0.5% crystal violet, and colonies containing >50 cells manually counted.
Concentrations 0~3μM
Incubation time 48 h
Animal Experiment
Animal models A375 melanoma human tumor xenograft model in female nu/nu mice
Formulation normal saline
Dosages 100 and 125 mg/kg daily
Administration i.p.
Chemical Information
Molecular Weight 394.36
Formula C15H12F2N6O3S
CAS Number 443797-96-4
Solubility (25°C) DMSO 69 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Emanuel S, et al. Cancer Res. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.

Related CDK Products
ARTS-021

ARTS-021 is a potent, reversible, orally available cyclin-dependent kinase 2 (CDK 2) selective inhibitor that inhibits CDK2 at nanomolar potency and with over 600-fold selectivity against CDK1.

T025

T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with Kd values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively.

PF-07224826

PF-07224826 is a CDK2/4/6 inhibitor.

INCB123667

INCB123667 is a CDK2 inhibitor.

Senexin B

Senexin B is a potent, orally active CDK8/19 inhibitor with Kd values of 140 nM and 80 nM for CDK8 and CDK19, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: JNJ-7706621, JNJ7706621 supplier, CDK, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.